A review on dynamics of permeability-glycoprotein in efflux of chemotherapeutic drugs

Priyanka Rani, Pranabesh Mandal, Bikash Kumar Rajak, Durg Vijay Singh
{"title":"A review on dynamics of permeability-glycoprotein in efflux of chemotherapeutic drugs","authors":"Priyanka Rani, Pranabesh Mandal, Bikash Kumar Rajak, Durg Vijay Singh","doi":"10.3389/fddsv.2024.1363364","DOIUrl":null,"url":null,"abstract":"Permeability-glycoprotein (P-gp) belongs to the ABS transporter protein family, with a high expression rate in cancerous cells. The substrate/inhibitors of the protein are structurally diverse, with no lucid mechanism of inhibition. There are two schools of thought on the inhibition mechanism: (i) P-gp inhibitors bind to the huge hydrophobic cavity between two Trans-Membrane Domains (TMDs), supported by ample literary proof and (ii) P-gp inhibitors bind to the vicinity of Nucleotide-Binding Sites (NBSs). Structural biologists have presented several experimental and theoretical structures of P-gp with bound nucleotides and inhibitors to explain the same. However, the available experimental P-gp structures are insufficient to address the catalytic transition path of mammalian P-gp in detail, thus the dynamics and mechanism by which drugs are effluxed is still unknown. Targeted Molecular Dynamics (targeted MD) could be used to minutely analyse and explore the catalytic transition inward open (IO) to outward open (OO) and relaxation path (OO to IO). Finally, analysis of targeted MD trajectory may help to explore different conformational states of Pg-p (reaction coordinate of catalytic transition/relaxation), efflux of compounds aided by the dynamics of Nucleotide Binding Domains/NBDs (ATP coupled process) and TMDs (peristalsis-like movement pushes the bound molecule). This review presents an understanding of the catalytic transition and dynamics of protein which provides insights at the efflux of chemotherapeutic drug using in cancer treatment.","PeriodicalId":507971,"journal":{"name":"Frontiers in Drug Discovery","volume":"37 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fddsv.2024.1363364","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Permeability-glycoprotein (P-gp) belongs to the ABS transporter protein family, with a high expression rate in cancerous cells. The substrate/inhibitors of the protein are structurally diverse, with no lucid mechanism of inhibition. There are two schools of thought on the inhibition mechanism: (i) P-gp inhibitors bind to the huge hydrophobic cavity between two Trans-Membrane Domains (TMDs), supported by ample literary proof and (ii) P-gp inhibitors bind to the vicinity of Nucleotide-Binding Sites (NBSs). Structural biologists have presented several experimental and theoretical structures of P-gp with bound nucleotides and inhibitors to explain the same. However, the available experimental P-gp structures are insufficient to address the catalytic transition path of mammalian P-gp in detail, thus the dynamics and mechanism by which drugs are effluxed is still unknown. Targeted Molecular Dynamics (targeted MD) could be used to minutely analyse and explore the catalytic transition inward open (IO) to outward open (OO) and relaxation path (OO to IO). Finally, analysis of targeted MD trajectory may help to explore different conformational states of Pg-p (reaction coordinate of catalytic transition/relaxation), efflux of compounds aided by the dynamics of Nucleotide Binding Domains/NBDs (ATP coupled process) and TMDs (peristalsis-like movement pushes the bound molecule). This review presents an understanding of the catalytic transition and dynamics of protein which provides insights at the efflux of chemotherapeutic drug using in cancer treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
化疗药物外流过程中渗透性糖蛋白的动力学综述
渗透性糖蛋白(P-gp)属于 ABS 转运体蛋白家族,在癌细胞中的表达率很高。该蛋白的底物/抑制剂结构多样,没有明确的抑制机制。关于抑制机制有两种观点:(i) P-gp 抑制剂与两个跨膜结构域(TMD)之间的巨大疏水空腔结合,这一点有大量文献证明;(ii) P-gp 抑制剂与核苷酸结合位点(NBS)附近结合。结构生物学家提出了几种 P-gp 与核苷酸和抑制剂结合的实验和理论结构,以解释这一现象。然而,现有的 P-gp 实验结构不足以详细解释哺乳动物 P-gp 的催化转换路径,因此药物外流的动力学和机制仍然未知。靶向分子动力学(targeted Molecular Dynamics,MD)可用于详细分析和探索内向开放(IO)到外向开放(OO)的催化转换以及弛豫路径(OO 到 IO)。最后,靶向 MD 轨迹分析可能有助于探索 Pg-p(催化转换/松弛的反应坐标)的不同构象状态,以及核苷酸结合域/NBDs(ATP 耦合过程)和 TMDs(推动结合分子的蠕动)的动态辅助下的化合物外流。这篇综述介绍了对蛋白质催化转换和动力学的理解,为癌症治疗中化疗药物的外流提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The role of physicochemical and topological parameters in drug design Editorial: Recent trends in anti-cancer drug discovery by in silico methods A small molecule inhibitor of leucine carboxyl methyltransferase-1 inhibits cancer cell survival A review on dynamics of permeability-glycoprotein in efflux of chemotherapeutic drugs The (misleading) role of animal models in drug development
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1